CD8A and neoplasm: Thirty-five percent of the CD8+ tumor infiltrating T cells stained brightly with OVA257:Kb tetramer B16-OVA tumor, indicating that the epitope-modified vaccine delivered at a remote site can influence the quality of the T-cell response at the tumor.